Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VENKAT PAVAN R KANCHARLA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205091758
CMS profile
99298
Location
PALM BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$8,764.77

260 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $7,581.55 246
Long term medical supply or device loan $1,014.85 11
Education $168.37 3

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $1,407.85 34
Janssen Biotech, Inc. $661.24 14
Amgen Inc. $525.82 12
E.R. Squibb & Sons, L.L.C. $491.53 12
Genentech USA, Inc. $452.51 6
AstraZeneca Pharmaceuticals LP $328.90 13
Seagen Inc. $326.07 10
GENZYME CORPORATION $321.99 11
Celgene Corporation $298.27 9
Regeneron Healthcare Solutions, Inc. $266.53 3
Merck Sharp & Dohme Corporation $247.83 14
Eisai Inc. $244.03 7
Incyte Corporation $200.37 8
Daiichi Sankyo Inc. $197.17 6
Takeda Pharmaceuticals U.S.A., Inc. $190.40 2
GlaxoSmithKline, LLC. $176.26 4
Dova Pharmaceuticals $168.02 4
Myovant Sciences Inc. $150.23 3
Blueprint Medicines Corporation $135.00 1
BeiGene USA, Inc. $126.05 1
PFIZER INC. $121.13 8
Kite Pharma, Inc. $120.29 3
Novocure Inc. $118.98 1
Karyopharm Therapeutics Inc. $118.62 7
EMD Serono, Inc. $115.56 1
G1 Therapeutics, Inc. $110.30 1
Lilly USA, LLC $105.67 6
Boehringer Ingelheim Pharmaceuticals, Inc. $99.11 5
Astellas Pharma US Inc $81.96 5
Bayer HealthCare Pharmaceuticals Inc. $75.84 5
JAZZ PHARMACEUTICALS INC. $69.78 4
Ipsen Biopharmaceuticals, Inc $54.10 4
MorphoSys, US Inc. $51.90 3
Dendreon Pharmaceuticals LLC $50.62 2
Pharmacosmos Therapeutics Inc. $42.23 2
Pharmacyclics LLC, An AbbVie Company $41.61 2
Taiho Oncology, Inc. $38.32 2
Nevro Corp. $33.65 2
AMAG Pharmaceuticals, Inc. $31.14 2
Deciphera Pharmaceuticals Inc. $29.71 2
PUMA BIOTECHNOLOGY, INC. $29.06 2
Acceleron Pharma, Inc. $27.53 2
Kyowa Kirin, Inc. $26.46 1
Emmaus Medical, Inc. $24.26 1
TG THERAPEUTICS, INC. $24.11 1
AbbVie Inc. $22.34 1
Mylan Institutional Inc. $21.87 1
Servier Pharmaceuticals LLC $19.87 1
Medtronic, Inc. $18.87 1
Heron Therapeutics, Inc. $17.91 1
Alexion Pharmaceuticals, Inc. $17.49 1
Exelixis Inc. $17.44 1
Global Blood Therapeutics, Inc. $16.22 1
Clovis Oncology, Inc. $16.00 1
ARRAY BIOPHARMA INC $15.75 1
Gilead Sciences, Inc. $11.92 1
Secura Bio, Inc. $11.08 1

Page 3 of 6; records 101–150 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VENKAT PAVAN R KANCHARLA

NPI 1205091758 · CMS profile ID 99298

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PALM BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 260 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1205091758?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

260 matching records · $8,764.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 260 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 260.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $6.1108/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825853883 CMS
Pharmacosmos Therapeutics Inc. $22.2308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842717713 CMS
Lilly USA, LLC $15.4308/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818820603 CMS
Merck Sharp & Dohme Corporation $15.4208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848516249 CMS
JAZZ PHARMACEUTICALS INC. $15.0608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845555913 CMS
Novartis Pharmaceuticals Corporation $99.7008/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740471 CMS
PUMA BIOTECHNOLOGY, INC. $15.7908/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834092659 CMS
AstraZeneca Pharmaceuticals LP $13.4408/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834342469 CMS
G1 Therapeutics, Inc. $110.3008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840102539 CMS
GlaxoSmithKline, LLC. $17.8508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801654413 CMS
Janssen Biotech, Inc. $16.1508/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787982953 CMS
E.R. Squibb & Sons, L.L.C. $18.0908/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783598255 CMS
Janssen Biotech, Inc. $15.6908/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787982955 CMS
Amgen Inc. $118.5708/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826451406 CMS
Lilly USA, LLC $18.5708/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818820607 CMS
Global Blood Therapeutics, Inc. $16.2207/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835340189 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.2507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763658676 CMS
Janssen Biotech, Inc. $125.0007/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787982945 CMS
AMAG Pharmaceuticals, Inc. $16.7407/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847690467 CMS
E.R. Squibb & Sons, L.L.C. $16.1707/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783598257 CMS
Dendreon Pharmaceuticals LLC $25.6707/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851428091 CMS
Novartis Pharmaceuticals Corporation $21.5007/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740439 CMS
Merck Sharp & Dohme Corporation $20.6807/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848687387 CMS
PFIZER INC. $14.9807/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832578937 CMS
Deciphera Pharmaceuticals Inc. $14.2907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826795887 CMS
Novartis Pharmaceuticals Corporation $20.0607/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740437 CMS
Amgen Inc. $30.3707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825853887 CMS
Seagen Inc. $101.6007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832158769 CMS
Merck Sharp & Dohme Corporation $19.9407/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848706075 CMS
GENZYME CORPORATION $20.2507/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843638375 CMS
Eisai Inc. $18.5407/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817986181 CMS
GENZYME CORPORATION $13.8907/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843638359 CMS
Dova Pharmaceuticals $20.0607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849751051 CMS
Incyte Corporation $17.8007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835546961 CMS
Eisai Inc. $120.3306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833770307 CMS
Merck Sharp & Dohme Corporation $17.8806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848530205 CMS
PFIZER INC. $16.4006/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832680131 CMS
Acceleron Pharma, Inc. $11.5706/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843319355 CMS
Novartis Pharmaceuticals Corporation $18.3406/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740435 CMS
Blueprint Medicines Corporation $135.0006/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848932867 CMS
Seagen Inc. $18.3706/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832158673 CMS
E.R. Squibb & Sons, L.L.C. $13.3106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783598239 CMS
Daiichi Sankyo Inc. $15.2606/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836295811 CMS
AstraZeneca Pharmaceuticals LP $24.8806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834330795 CMS
Novartis Pharmaceuticals Corporation $99.7006/16/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740469 CMS
Amgen Inc. $20.9406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826451381 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3006/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763658678 CMS
Novartis Pharmaceuticals Corporation $7.8406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812740433 CMS
PFIZER INC. $14.4406/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832646113 CMS
AstraZeneca Pharmaceuticals LP $15.8406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834322871 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,389.78 246
PY2020 $6,391.92 188
PY2021 $8,764.77 260
PY2022 $10,106.54 262
PY2023 $9,492.12 270
PY2024 $14,184.27 287
PY2025 $30,766.14 249

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $150.00 1
PY2025 Principal investigator $419,595.67 125
PY2024 Principal investigator $260,104.53 173
PY2023 Principal investigator $194,397.52 62
PY2022 Principal investigator $150,869.81 31
PY2021 Recipient $1,417.45 1
PY2021 Principal investigator $239,699.09 27
PY2020 Recipient $4,360.00 1
PY2020 Principal investigator $85,814.19 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547707
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706757
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706759
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706761
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706863
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706937
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706939
Principal investigator 1 PFIZER INC. $3,187.76 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706941
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707876
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707878
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707880
Principal investigator 1 BioNTech SE $245.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019328
Principal investigator 1 BioNTech SE $245.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019580
Principal investigator 1 Eli Lilly and Company $90.00 11/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891602
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387493
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019570
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019576
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388265
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365263
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365267
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726426
Principal investigator 1 Daiichi Sankyo Inc. $4,774.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387491
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749102
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387487
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388261
Principal investigator 1 Daiichi Sankyo Inc. $588.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388263
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941475
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941498
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941579
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941591
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941607
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941697
Principal investigator 1 PFIZER INC. $1,641.00 08/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228720619
Principal investigator 1 PFIZER INC. $500.00 08/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744375
Principal investigator 1 PFIZER INC. $723.00 08/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228766741
Principal investigator 1 Daiichi Sankyo Inc. $6,058.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387489
Principal investigator 1 Genentech, Inc. $1,500.00 07/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676413
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard - Melbourne Pine
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941554
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743942
Principal investigator 1 PFIZER INC. $2,518.00 06/16/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228790391
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387485
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228723076
Principal investigator 1 Genentech, Inc. $4,089.00 05/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676346
Principal investigator 1 Genentech, Inc. $1,350.00 05/12/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681522
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,534.80 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547699
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,712.07 04/30/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547697
Principal investigator 1 Eli Lilly and Company $18,227.00 04/29/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187892426
Principal investigator 1 Genentech, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676312
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365261
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365265
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medi
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941633
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medi
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941685
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745173
Principal investigator 1 PFIZER INC. $860.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745952
Principal investigator 1 PFIZER INC. $250.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746511
Principal investigator 1 Genentech, Inc. $2,168.00 04/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676333
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387473
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387475
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387477
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387479
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387481
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387483
Principal investigator 1 PFIZER INC. $9,011.00 03/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228795253
Principal investigator 1 Eli Lilly and Company $565.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187887098
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941563
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 03/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941647
Principal investigator 1 PFIZER INC. $750.00 03/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744710
Principal investigator 1 PFIZER INC. $3,231.00 03/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749168
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,000.00 03/05/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547703
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387229
Recipient Eli Lilly and Company $150.00 02/15/2025 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 1187873605
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941484
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941509
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941528
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941541
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941657
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941675
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941707
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941718
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743947
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744132
Principal investigator 1 PFIZER INC. $281.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744312
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744316
Principal investigator 1 PFIZER INC. $750.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744383
Principal investigator 1 PFIZER INC. $2,147.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744659
Principal investigator 1 PFIZER INC. $2,200.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744830
Principal investigator 1 PFIZER INC. $50.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745726
Principal investigator 1 PFIZER INC. $2,931.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747838
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747842
Principal investigator 1 PFIZER INC. $1,843.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747943
Principal investigator 1 PFIZER INC. $2,042.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747947
Principal investigator 1 Daiichi Sankyo Inc. $6,451.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387197
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387199
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387201
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387203
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387205
Principal investigator 1 Daiichi Sankyo Inc. $90.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387207
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387209
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387211
Principal investigator 1 Daiichi Sankyo Inc. $236.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387213
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387215
Principal investigator 1 Eli Lilly and Company $0.04 02/06/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187886856
Principal investigator 1 Genentech, Inc. $1,350.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681550
Principal investigator 1 Genentech, Inc. $1,500.00 02/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676261
Principal investigator 1 PFIZER INC. $13,605.00 02/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228791554
Principal investigator 1 Eli Lilly and Company $0.14 01/28/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187874607
Principal investigator 1 Eli Lilly and Company $65,656.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187893264
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,060.65 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547701
Principal investigator 1 Amgen Inc. $1,483.36 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246639885
Principal investigator 1 AstraZeneca Pharmaceuticals LP $680.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547695
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,040.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185547705
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365269
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365271
Principal investigator 1 Eli Lilly and Company $956.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187874609
Principal investigator 1 Eli Lilly and Company $105,839.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187875431
Principal investigator 1 Eli Lilly and Company $31,772.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187876523
Principal investigator 1 Eli Lilly and Company $1,549.95 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
Not supplied No dispute reported 06/30/2026 1187880619
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941520
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941621
Principal investigator 1 PFIZER INC. $3,231.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743939
Principal investigator 1 PFIZER INC. $281.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744181
Principal investigator 1 PFIZER INC. $151.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744308
Principal investigator 1 PFIZER INC. $750.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744379
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746902
Principal investigator 1 Eli Lilly and Company $1.29 01/06/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187878255